References

1.     Gaze MN, Chang Y-C, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of Dosimetry-Based High-Dose 131I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma. Cancer Biotherapy & Radiopharmaceuticals 2005;20:195–199. https://doi.org/10.1089/cbr.2005.20.195. 

2.     Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging 2008;35:1039–1047. https://doi.org/10.1007/s00259-008-0715-3.

3.     Vöö S, Bucerius J, Mottaghy FM. I-131-MIBG therapies. Methods 2011;55:238–245. https://doi.org/10.1016/j.ymeth.2011.10.006.

4.     Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin Nuclear Medicine 2006;45:145–51; quiz N39–40. 16964339.

5.     Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nuclear Medicine Communications 1992;13:513–21.10.1097/00006231-199207000-00006

6.     Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma. Journal of Clinical Oncology 2009;27:4162–4168. https://doi.org/10.1200/JCO.2008.21.3496. 

7.     George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, et al. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nuclear Medicine Communications 2016;37:466–472. https://doi.org/10.1097/MNM.0000000000000470. 

8.     Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, et al. Dosimetry for Fractionated 131 I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results. Cancer Biotherapy & Radiopharmaceuticals 2007;22:105–112. https://doi.org/10.1089/cbr.2007.301. 

9.     Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 1984;25:197–206.PMID: 6726430

10.     Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging 2010;37:1279–1290. https://doi.org/10.1007/s00259-010-1391-7. 

11.     Gear J, Chiesa C, Lassmann M, Gabiña PM, Tran-Gia J, Stokke C, et al. EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours. EJNMMI Phys 2020;7:15. https://doi.org/10.1186/s40658-020-0282-7.

12.     Mínguez P, Flux G, Genollá J, Guayambuco S, Delgado A, Fombellida JC, et al. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumours with 131I-metaiodobenzylguanidine with implications for the activity to administer. Medical Physics 2015;42:3969–3978. https://doi.org/10.1118/1.4921807. 

13.     Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumour and whole-body dosimetry with tumour response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2001;42:1713–21.11696644. 

14.     Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma. Journal of Nuclear Medicine 2009;50:1518–1524. https://doi.org/10.2967/jnumed.109.064469.

15.     Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. Journal of Clinical Oncology 1992;10:1889–1896. https://doi.org/10.1200/JCO.1992.10.12.1889.

16.     Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary Myelodysplastic Syndrome and Leukaemia Following 131 I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma n.d. 10.1097/00043426-200307000-00009